RemeGen stock closed at HK$64.85 on 30 October, after a choppy month that left the shares down about 16% over 30 days and roughly 21% over three months. That short term drift jars with the fresh Q3 2026 print, where the biotech reported CNY 910.5m in revenue and basic earnings per share of CNY 1.09, alongside a trailing twelve month P/E near 4.7x. The immediate price action indicates traders are focused on the next few quarters. The earnings profile and discounted cash flow valuation place the core discussion several years into the future.
Like the RemeGen earnings story but want more ideas with beaten down share prices and current profits to back them up? Compare Benchmark SEHK:9995 against our screener of 199 high quality undervalued stocks .
Q3 2026 Earnings Summary
-
Revenue (Q3 2026 vs Q3 2025):CNY 910.5m vs. CNY 621.9m (up about 46%)
-
Net Income, excluding extra items (Q3 2026 vs Q3 2025):CNY 610.9m profit vs. CNY 101.1m loss (swing into profit)
-
Basic EPS (Q3 2026 vs Q3 2025):CNY 1.09 vs. a loss of CNY 0.18 per share (return to positive earnings per share)
-
R&D Pipeline, products in late stage and pre registration (Q2 2026 vs Q2 2025):Phase III 10 vs. 2; Pre registration 10 vs. 4 (expanded late stage pipeline)
RemeGen's profit is up but forecasts point down. Ask Charlie what makes RemeGen look this cheap .
RemeGen bullish story leans on profit and pipeline
For anyone backing a positive view on RemeGen, the latest quarter gives some support. Revenue sits at CNY 910.5m and management reports a swing to a CNY 610.9m profit from a prior loss. Earnings per share of CNY 1.09 now run alongside a bigger late stage pipeline, with Phase III and pre registration projects both expanded. That mix of current profitability and more shots on goal in advanced trials lines up with a platform style autoimmune and oncology story.
Bear case focuses on volatility and execution risk
Bears will point straight to the share price. The stock is down about 16% over 30 days and roughly 21% over three months, so sentiment clearly lags the headline Q3 profit. That disconnect keeps execution risk in focus. A larger late stage pipeline also raises questions about future research spending and capital needs. Recent strong Phase 3 readouts for telitacicept help reduce clinical risk on key assets, yet the breadth of programs still leaves plenty of room for setbacks to hit confidence.
Do Wall Street analysts think RemeGen's mix of current profit and a deeper late stage pipeline deserves a higher valuation multiple? Check the consensus price target analysis for RemeGen .
Hunt For Mispriced Earnings Power
RemeGen reports a profitable quarter while its share price moves in a different direction. The real opportunity lies in stocks that may be undervalued before broader market expectations adjust.
-
Company 1 - 39% below our estimate - taps growing electrification, decarbonization and data demand by securing control positions in key infrastructure operators.
-
Company 2 - 40% below our estimate - layers an agentic AI platform onto web and cloud subscribers so accounts adopt higher value digital services.
-
Company 3 - 31% below our estimate - supplies AI infrastructure supporting superclusters that large model providers use when scaling beyond a single cloud relationship.
Three companies from the same screener. Open every one of the 199 undervalued companies on it →
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include 9995.HK .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
